Institution Directory

Clinical trials at UCLA Health

Sites in Los Angeles, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1096

Shown on this page

Current sort

Live official records

Conditions: Metastatic Non Small Cell Lung Cancer
Interventions: Datopotamab Deruxtecan, Pembrolizumab; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 31
States / cities: Chandler, Arizona • Los Angeles, California • Santa Barbara, California + 19 more

Conditions: Rheumatoid Arthritis
Interventions: targeted synthetic DMARD class, non-TNFi-biologic class; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 924 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 48
States / cities: Auburn, Alabama • Birmingham, Alabama • Peoria, Arizona + 41 more

Conditions: Fabry Disease
Interventions: AMT-191; Drug
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 7 more

Conditions: Low Vision, Low Vision Aids
Interventions: Low Vision Rehabilitation; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Fullerton, California • Grass Valley, California • Los Angeles, California + 6 more

Conditions: Lung Transplant Rejection
Interventions: Belumosudil, Azithromycin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Sleep Disturbance, Inflammation, Psychosocial Functioning
Interventions: Mindfulness Meditation, Sleep Education; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 22 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Interventions: daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more

Conditions: Lung Diseases
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 25 Years to 35 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 37
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Lymphoma, Mantle-Cell
Interventions: Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 36
States / cities: Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: Inflammatory Bowel Disease (IBD), Anemia, Inflammatory Bowel Disease (IBD); Anemia
Interventions: DISC-0974, Placebo; Drug
Lead sponsor: Disc Medicine, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 10 more

Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine, nab-paclitaxel, RMC-9805, FOLFIRI regimen; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 32
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Interventions: Tulisokibart, Companion diagnostic ( CDx), Placebo; Drug · Diagnostic Test
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more

About this UCLA Health institution page

What this page lists: ClinicalTrials.gov records that list UCLA Health in Los Angeles, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UCLA Health

Filter and sort this campus

Live official records

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

RA-PRO PRAGMATIC TRIAL

Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease

Beacon Sensors and Telerehabilitation to Assess and Improve Use of Devices (BeST-AID) for Low Vision

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

UCLA REST Study (REsearch on Sleep Techniques)

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

American Lung Association (ALA) Lung Health Cohort

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Study of DISC-0974-201 in Participants With IBD and Anemia

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

About this UCLA Health institution page